{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:19Z","timestamp":1790912479356,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Vaccines Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Takeda\u2019s dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children (20 099, 4\u201316 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 months apart and are under surveillance to detect dengue by serotype-specific RT-PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cumulative efficacy against dengue approximately 27 months since first dose was 72.7% (95% confidence interval [CI], 67.1%\u201377.3%), including 67.0% (95% CI, 53.6%\u201376.5%) in dengue-naive and 89.2% (95% CI, 82.4%\u201393.3%) against hospitalized dengue. In the second year, decline in efficacy was observed (56.2%; 95% CI, 42.3%\u201366.8%) with the largest decline in 4\u20135 year olds (24.5%; 95% CI, \u221234.2% to 57.5%); efficacy was 60.6% (95% CI, 43.8%\u201372.4%) in 6\u201311 year and 71.2% (95% CI, 41.0%\u201385.9%) in 12\u201316 year age groups. As TAK-003 efficacy varies by serotype, changes in serotype dominance partially contributed to efficacy differences in year-by-year analysis. No related serious adverse events occurred during the second year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TAK-003 demonstrated continued benefit independent of baseline serostatus in reducing dengue with some decline in efficacy during the second year. Three-year data will be important to see if efficacy stabilizes or declines further.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT02747927.<\/jats:p>\n                    <jats:p>Takeda\u2019s tetravalent dengue vaccine (TAK-003) continued to demonstrate benefit in reducing dengue independent of baseline serostatus up to 2 years after completing vaccination with some decline in efficacy during the second year in 4\u201316 year olds in dengue-endemic countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa761","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T15:23:49Z","timestamp":1607613829000},"page":"1521-1532","source":"Crossref","is-referenced-by-count":102,"title":["Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination"],"prefix":"10.1093","volume":"225","author":[{"given":"Eduardo","family":"L\u00f3pez-Medina","sequence":"first","affiliation":[{"name":"Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica, Universidad del Valle and Centro M\u00e9dico Imbanaco, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saez-Llorens","sequence":"additional","affiliation":[{"name":"Hospital del Ni\u00f1o Dr Jos\u00e9 Ren\u00e1n Esquivel, Sistema Nacional de Investigaci\u00f3n, Secretaria Nacional de Ciencia y Tecnologia, Centro de Vacunaci\u00f3n Internacional, Panama City, Panama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Borja-Tabora","sequence":"additional","affiliation":[{"name":"Research Institute for Tropical Medicine, Muntinlupa, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Bravo","sequence":"additional","affiliation":[{"name":"University of the Philippines Manila, Ermita, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukiat","family":"Sirivichayakul","sequence":"additional","affiliation":[{"name":"Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Martinez","family":"Vargas","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica Dominicana, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Theresa","family":"Alera","sequence":"additional","affiliation":[{"name":"Philippines-Armed Forces Research Institute of Medical Sciences Virology Research Unit, Cebu City, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Vel\u00e1squez","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica, Acacias, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Reynales","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica, Yopal, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rivera","sequence":"additional","affiliation":[{"name":"Hospital Maternidad Nuestra Senora de Altagracia, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerachai","family":"Watanaveeradej","sequence":"additional","affiliation":[{"name":"Phramongkutklao Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith Johana","family":"Rodriguez-Arenales","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica, Aguazul, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Yu","sequence":"additional","affiliation":[{"name":"De La Salle Medical and Health Sciences Institute, Dasmari\u00f1as, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Espinoza","sequence":"additional","affiliation":[{"name":"National Autonomous University of Nicaragua, Le\u00f3n, Nicaragua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynaldo","family":"Dietze","sequence":"additional","affiliation":[{"name":"Universidade Federal Do Espirito Santo, Hospital Universit\u00e1rio Cassiano Ant\u00f4nio de Moraes, Vit\u00f3ria, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lak Kumar","family":"Fernando","sequence":"additional","affiliation":[{"name":"Centre for Clinical Management of Dengue and Dengue Haemorrhagic Fever, Negombo General Hospital, Negombo, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pujitha","family":"Wickramasinghe","sequence":"additional","affiliation":[{"name":"University of Colombo, Colombo, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edson","family":"Duarte Moreira","sequence":"additional","affiliation":[{"name":"Associa\u00e7\u00e3o Obras Sociais Irm\u00e3 Dulce Hospital Santo Ant\u00f4nio and Oswaldo Cruz Foundation, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asvini D","family":"Fernando","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulanie","family":"Gunasekera","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Sri Jayawardenenpura, Nugegoda, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleber","family":"Luz","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Tropical da Universidade Federal do Rio Grande do Norte, Natal, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivaldo Ven\u00e2ncio","family":"da Cunha","sequence":"additional","affiliation":[{"name":"Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rauscher","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Liu","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"LeFevre","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pope","family":"Kosalaraksa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"2022050519470546700_CIT0001","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2022050519470546700_CIT0002","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"2022050519470546700_CIT0003","doi-asserted-by":"crossref","first-page":"e0007213","DOI":"10.1371\/journal.pntd.0007213","article-title":"Global expansion and redistribution of Aedes-borne virus transmission risk with climate change","volume":"13","author":"Ryan","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2022050519470546700_CIT0004","first-page":"457","article-title":"Dengue vaccine: WHO position paper\u2014September 2018","volume":"93","author":"World Health Organization.","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"2022050519470546700_CIT0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2022050519470546700_CIT0006","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022050519470546700_CIT0007","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/infdis\/jiv258","article-title":"CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate","volume":"212","author":"Chu","year":"2015","journal-title":"J Infect Dis"},{"key":"2022050519470546700_CIT0008","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"key":"2022050519470546700_CIT0009","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"2022050519470546700_CIT0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022050519470546700_CIT0011","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"2022050519470546700_CIT0012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022050519470546700_CIT0013","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022050519470546700_CIT0014","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"key":"2022050519470546700_CIT0015","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"2022050519470546700_CIT0016","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"2022050519470546700_CIT0017","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"2022050519470546700_CIT0018","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"2022050519470546700_CIT0019","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2020.03.029","article-title":"Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"2022050519470546700_CIT0020","author":"World Medical Association"},{"key":"2022050519470546700_CIT0021","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)"},{"key":"2022050519470546700_CIT0022","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"2022050519470546700_CIT0023","volume-title":"Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control","author":"World Health Organization (WHO)","year":"1997","edition":"2"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa761\/36195884\/jiaa761.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1521\/43546369\/jiaa761.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1521\/43546369\/jiaa761.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:29:56Z","timestamp":1651768196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/9\/1521\/6034203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,12,15]]},"published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa761","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2020,12,15]]}}}